Literature DB >> 3053189

The effect of human growth hormone therapy on skinfold thickness in growth hormone-deficient children.

J M Wit1, M A van't Hof, J L Van den Brande.   

Abstract

Skinfold thickness (ST) was measured in 43 children with various forms of growth hormone (GH) deficiency during the first year of GH therapy. The average (and SEM) initial ST, expressed as standard deviation score (SDS) was 1.17 (0.25) for subscapular, 0.63 (0.18) for triceps, and 0.40 (0.21) for biceps ST. During therapy the average decrease is 1 SD. Children in the pubertal age group and those with partial GH deficiency showed smaller decreases. A larger decrease of triceps ST was associated with lower GH and insulin peaks, and lower age, bone age and initial weight-for-height. Some correlations between ST decrease and growth response in the first year were significant, but still too low to allow of reliable predictions. The same was true for other clinical parameters. These data indicate that a chronic lack of GH leads to unequal fat distribution, possibly due to different sensitivities to GH in the trunk and extremities. The variability of ST responses to GH therapy limits clinical applications.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3053189     DOI: 10.1007/BF00442469

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  24 in total

1.  Revised standards for triceps and subscapular skinfolds in British children.

Authors:  J M Tanner; R H Whitehouse
Journal:  Arch Dis Child       Date:  1975-02       Impact factor: 3.791

2.  [Long-term treatment of hypophyseal growth disorders with human growth hormone; results in 38 Dutch children].

Authors:  J H Verbeek; R Steendijk; A Bot; J J van der Werff ten Bosch
Journal:  Ned Tijdschr Geneeskd       Date:  1979-03-31

3.  Growth and body composition in intrauterine growth retardation (IUGR) before and during human growth hormone administration.

Authors:  P A Lee; R M Blizzard; D B Cheek; A B Holt
Journal:  Metabolism       Date:  1974-10       Impact factor: 8.694

4.  A comparison of the growth-promoting, lipolytic, diabetogenic and immunological properties of pituitary and recombinant-DNA-derived bovine growth hormone (somatotropin).

Authors:  I C Hart; P M Chadwick; T C Boone; K E Langley; C Rudman; L M Souza
Journal:  Biochem J       Date:  1984-11-15       Impact factor: 3.857

5.  Dose dependence of growth response to human growth hormone in growth hormone deficiency.

Authors:  M A Preece; J M Tanner; R H Whitehouse; N Cameron
Journal:  J Clin Endocrinol Metab       Date:  1976-03       Impact factor: 5.958

6.  Experience with human growth hormone in Great Britain: the report of the MRC Working Party.

Authors:  R D Milner; T Russell-Fraser; C G Brook; P M Cotes; J W Farquhar; J M Parkin; M A Preece; G J Snodgrass; A S Mason; J M Tanner; F P Vince
Journal:  Clin Endocrinol (Oxf)       Date:  1979-07       Impact factor: 3.478

7.  Comparative rapidity of response of height, limb muscle and limb fat to treatment with human growth hormone in patients with and without growth hormone deficiency.

Authors:  J M Tanner; P C Hughes; R H Whitehouse
Journal:  Acta Endocrinol (Copenh)       Date:  1977-04

8.  Biological activity of bacterial derived human growth hormone in adipose tissue of hypophysectomized rats.

Authors:  H M Goodman
Journal:  Endocrinology       Date:  1984-01       Impact factor: 4.736

9.  Effect of human growth hormone treatment on adipose tissue in children.

Authors:  C G Brook
Journal:  Arch Dis Child       Date:  1973-09       Impact factor: 3.791

10.  Reference curves for biceps, triceps, subscapular and suprailiac skinfolds in Dutch children from 7-14 years.

Authors:  J M Wit; M A van 't Hof; M J Roede
Journal:  Growth       Date:  1984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.